T-cel and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation by Using Immunomagnetic Negative and Positive Selection Procedures View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2006-

ABSTRACT

T-cell and B-cell depletion in allogeneic peripheral blood stem cell transplantation by using immunomagnetic negative and positive selection procedures Background: Removal of T-cells from the donor graft (T-cell depletion) offers the possibility for prevention of GVHD and subsequently less transplant related morbidity and mortality after allogeneic stem cell transplantation (SCT). There are several techniques to deplete T-cells from the stem cell grafts e.g. physical, immunological and combined physical / immunological separation methods. All these techniques result in a stem cell graft with sufficient CD34+ stem cells combined with an adequate depletion of T and B cells. CD34+ selected stem cell grafts are very pure and do not contain any additional cell populations. In contrast, CD3+/CD19+ depleted grafts still contain NK-cells, monocytes and dendritic cells that are part of the innate immune system. Theoretically,the presence of these cells may positively influence immunological reconstitution and the graft-versus-leukaemia (GVL) effect, respectively, resulting in improved outcome after SCT Objectives: To evaluate the differences in immunological reconstitution, transplant related mortality, disease-free survival and overall survival after T-cell depleted allogeneic SCT for haematological malignancies using either immunomagnetic CD34+ selection or immunomagnetic CD3+/CD19+ depletion using the CliniMACS system in approximately 270 consecutive patients. Additionally in this study in 20 consecutive patients the kinetics of NK-cel reconstitution and differences in NK-cell repertoire will be monitored. NK-cell mediated anti-tumor reactivity will be monitored in patients transplanted with and without NK-cells in the stem cell graft (CD3+/CD19+ depletion, versus CD34+ selection). Secondary objectives are to evaluate the clinical relevance of minor histocompatibility-specific cytotoxic T-cell responses for the GVL effect, the kinetics of NK-cell reconstitution and differences in NK-cell repertoire using the different T-cell depletion protocols. Design: Single center prospective randomised phase III study Population: Patients eligible for allogeneic SCT according to the standard criteria of our institution who will receive an allogeneic T- and B-cell depleted SCT with peripheral stem cells of an HLA-identical sibling donor or an HLA-identical unrelated voluntary (VUD) donor. Intervention: T-cell depletion will be conducted using two different techniques: either immunomagnetic CD34+ selection or immunomagnetic CD3+/CD19+ depletion. Endpoints: Primary endpoints are immunological reconstitution, relapse, disease free survival and overall survival. Secondary endpoints: NK-cell reconstitution and NK-cell mediated anti-tumour reactivity. Cytotoxic T-cell responses for the GVL effect. Estimated efforts and risks for participating patients: We don't expect any extra patient efforts or risks because T-cell depletion is a standard procedure in our clinic for many years. There is extensive experience with immunological T-cell depletion techniques. We hypothesize CD3+/CD19+ depletion will favour stem cell transplant outcome. Immunological and molecular biological studies will be performed on blood samples already obtained as part of the standard protocol. More... »

URL

https://clinicaltrials.gov/show/NCT00306332

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "T-cell and B-cell depletion in allogeneic peripheral blood stem cell transplantation by using immunomagnetic negative and positive selection procedures Background: Removal of T-cells from the donor graft (T-cell depletion) offers the possibility for prevention of GVHD and subsequently less transplant related morbidity and mortality after allogeneic stem cell transplantation (SCT). There are several techniques to deplete T-cells from the stem cell grafts e.g. physical, immunological and combined physical / immunological separation methods. All these techniques result in a stem cell graft with sufficient CD34+ stem cells combined with an adequate depletion of T and B cells. CD34+ selected stem cell grafts are very pure and do not contain any additional cell populations. In contrast, CD3+/CD19+ depleted grafts still contain NK-cells, monocytes and dendritic cells that are part of the innate immune system. Theoretically,the presence of these cells may positively influence immunological reconstitution and the graft-versus-leukaemia (GVL) effect, respectively, resulting in improved outcome after SCT Objectives: To evaluate the differences in immunological reconstitution, transplant related mortality, disease-free survival and overall survival after T-cell depleted allogeneic SCT for haematological malignancies using either immunomagnetic CD34+ selection or immunomagnetic CD3+/CD19+ depletion using the CliniMACS system in approximately 270 consecutive patients. Additionally in this study in 20 consecutive patients the kinetics of NK-cel reconstitution and differences in NK-cell repertoire will be monitored. NK-cell mediated anti-tumor reactivity will be monitored in patients transplanted with and without NK-cells in the stem cell graft (CD3+/CD19+ depletion, versus CD34+ selection). Secondary objectives are to evaluate the clinical relevance of minor histocompatibility-specific cytotoxic T-cell responses for the GVL effect, the kinetics of NK-cell reconstitution and differences in NK-cell repertoire using the different T-cell depletion protocols. Design: Single center prospective randomised phase III study Population: Patients eligible for allogeneic SCT according to the standard criteria of our institution who will receive an allogeneic T- and B-cell depleted SCT with peripheral stem cells of an HLA-identical sibling donor or an HLA-identical unrelated voluntary (VUD) donor. Intervention: T-cell depletion will be conducted using two different techniques: either immunomagnetic CD34+ selection or immunomagnetic CD3+/CD19+ depletion. Endpoints: Primary endpoints are immunological reconstitution, relapse, disease free survival and overall survival. Secondary endpoints: NK-cell reconstitution and NK-cell mediated anti-tumour reactivity. Cytotoxic T-cell responses for the GVL effect. Estimated efforts and risks for participating patients: We don't expect any extra patient efforts or risks because T-cell depletion is a standard procedure in our clinic for many years. There is extensive experience with immunological T-cell depletion techniques. We hypothesize CD3+/CD19+ depletion will favour stem cell transplant outcome. Immunological and molecular biological studies will be performed on blood samples already obtained as part of the standard protocol.", 
    "id": "sg:clinicaltrial.NCT00306332", 
    "keywords": [
      "cels", 
      "cell depletion", 
      "peripheral blood stem cell", 
      "selection procedure", 
      "T-cell and B-cell", 
      "depletion", 
      "T cell", 
      "donor graft", 
      "T cell depletion", 
      "possibility", 
      "prevention", 
      "GVHD", 
      "related morbidity", 
      "mortality", 
      "stem cell transplantation", 
      "technique", 
      "T lymphocyte", 
      "stem cell", 
      "separation method", 
      "CD34+ stem cell", 
      "cell", 
      "additional cell", 
      "contrast", 
      "monocyte", 
      "dendritic cell", 
      "innate immune system", 
      "reconstitution", 
      "improved outcome", 
      "difference", 
      "transplant-related mortality", 
      "Disease-Free Survival", 
      "overall survival", 
      "allogeneic stem cell transplantation", 
      "haematological malignancy", 
      "selection", 
      "consecutive patient", 
      "kinetics", 
      "cell repertoire", 
      "reactivity", 
      "patient", 
      "secondary objective", 
      "clinical relevance", 
      "cytotoxic T cell response", 
      "Phase III study", 
      "standard criterion", 
      "institution", 
      "sibling", 
      "Tissue Donor", 
      "intervention", 
      "different technique", 
      "endpoint", 
      "primary endpoint", 
      "Recurrence", 
      "secondary endpoint", 
      "risk", 
      "standard procedure", 
      "clinic", 
      "stem cell transplant", 
      "molecular biological study", 
      "blood sample", 
      "standard protocol"
    ], 
    "name": "T-cel and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation by Using Immunomagnetic Negative and Positive Selection Procedures", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00306332"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00002.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.5590.9", 
        "type": "Organization"
      }
    ], 
    "startDate": "2006-03-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1038/sj.leu.2402203", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001358787", 
          "https://doi.org/10.1038/sj.leu.2402203"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1702451", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003235075", 
          "https://doi.org/10.1038/sj.bmt.1702451"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1365-2141.1997.d01-3499.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050047455"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00306332"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00306332'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00306332'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00306332'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00306332'


 

This table displays all metadata directly associated to this object as RDF triples.

90 TRIPLES      15 PREDICATES      78 URIs      69 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00306332 schema:about anzsrc-for:3103
2 schema:description T-cell and B-cell depletion in allogeneic peripheral blood stem cell transplantation by using immunomagnetic negative and positive selection procedures Background: Removal of T-cells from the donor graft (T-cell depletion) offers the possibility for prevention of GVHD and subsequently less transplant related morbidity and mortality after allogeneic stem cell transplantation (SCT). There are several techniques to deplete T-cells from the stem cell grafts e.g. physical, immunological and combined physical / immunological separation methods. All these techniques result in a stem cell graft with sufficient CD34+ stem cells combined with an adequate depletion of T and B cells. CD34+ selected stem cell grafts are very pure and do not contain any additional cell populations. In contrast, CD3+/CD19+ depleted grafts still contain NK-cells, monocytes and dendritic cells that are part of the innate immune system. Theoretically,the presence of these cells may positively influence immunological reconstitution and the graft-versus-leukaemia (GVL) effect, respectively, resulting in improved outcome after SCT Objectives: To evaluate the differences in immunological reconstitution, transplant related mortality, disease-free survival and overall survival after T-cell depleted allogeneic SCT for haematological malignancies using either immunomagnetic CD34+ selection or immunomagnetic CD3+/CD19+ depletion using the CliniMACS system in approximately 270 consecutive patients. Additionally in this study in 20 consecutive patients the kinetics of NK-cel reconstitution and differences in NK-cell repertoire will be monitored. NK-cell mediated anti-tumor reactivity will be monitored in patients transplanted with and without NK-cells in the stem cell graft (CD3+/CD19+ depletion, versus CD34+ selection). Secondary objectives are to evaluate the clinical relevance of minor histocompatibility-specific cytotoxic T-cell responses for the GVL effect, the kinetics of NK-cell reconstitution and differences in NK-cell repertoire using the different T-cell depletion protocols. Design: Single center prospective randomised phase III study Population: Patients eligible for allogeneic SCT according to the standard criteria of our institution who will receive an allogeneic T- and B-cell depleted SCT with peripheral stem cells of an HLA-identical sibling donor or an HLA-identical unrelated voluntary (VUD) donor. Intervention: T-cell depletion will be conducted using two different techniques: either immunomagnetic CD34+ selection or immunomagnetic CD3+/CD19+ depletion. Endpoints: Primary endpoints are immunological reconstitution, relapse, disease free survival and overall survival. Secondary endpoints: NK-cell reconstitution and NK-cell mediated anti-tumour reactivity. Cytotoxic T-cell responses for the GVL effect. Estimated efforts and risks for participating patients: We don't expect any extra patient efforts or risks because T-cell depletion is a standard procedure in our clinic for many years. There is extensive experience with immunological T-cell depletion techniques. We hypothesize CD3+/CD19+ depletion will favour stem cell transplant outcome. Immunological and molecular biological studies will be performed on blood samples already obtained as part of the standard protocol.
3 schema:keywords CD34+ stem cell
4 Disease-Free Survival
5 GVHD
6 Phase III study
7 Recurrence
8 T cell
9 T cell depletion
10 T lymphocyte
11 T-cell and B-cell
12 Tissue Donor
13 additional cell
14 allogeneic stem cell transplantation
15 blood sample
16 cell
17 cell depletion
18 cell repertoire
19 cels
20 clinic
21 clinical relevance
22 consecutive patient
23 contrast
24 cytotoxic T cell response
25 dendritic cell
26 depletion
27 difference
28 different technique
29 donor graft
30 endpoint
31 haematological malignancy
32 improved outcome
33 innate immune system
34 institution
35 intervention
36 kinetics
37 molecular biological study
38 monocyte
39 mortality
40 overall survival
41 patient
42 peripheral blood stem cell
43 possibility
44 prevention
45 primary endpoint
46 reactivity
47 reconstitution
48 related morbidity
49 risk
50 secondary endpoint
51 secondary objective
52 selection
53 selection procedure
54 separation method
55 sibling
56 standard criterion
57 standard procedure
58 standard protocol
59 stem cell
60 stem cell transplant
61 stem cell transplantation
62 technique
63 transplant-related mortality
64 schema:name T-cel and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation by Using Immunomagnetic Negative and Positive Selection Procedures
65 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00306332
66 schema:sdDatePublished 2019-03-07T15:22
67 schema:sdLicense https://scigraph.springernature.com/explorer/license/
68 schema:sdPublisher N0e195c80cd464aefaf35a963f4b58d36
69 schema:sponsor https://www.grid.ac/institutes/grid.5590.9
70 schema:startDate 2006-03-01T00:00:00Z
71 schema:subjectOf sg:pub.10.1038/sj.bmt.1702451
72 sg:pub.10.1038/sj.leu.2402203
73 https://doi.org/10.1046/j.1365-2141.1997.d01-3499.x
74 schema:url https://clinicaltrials.gov/show/NCT00306332
75 sgo:license sg:explorer/license/
76 sgo:sdDataset clinical_trials
77 rdf:type schema:MedicalStudy
78 N0e195c80cd464aefaf35a963f4b58d36 schema:name Springer Nature - SN SciGraph project
79 rdf:type schema:Organization
80 anzsrc-for:3103 schema:inDefinedTermSet anzsrc-for:
81 rdf:type schema:DefinedTerm
82 sg:pub.10.1038/sj.bmt.1702451 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003235075
83 https://doi.org/10.1038/sj.bmt.1702451
84 rdf:type schema:CreativeWork
85 sg:pub.10.1038/sj.leu.2402203 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001358787
86 https://doi.org/10.1038/sj.leu.2402203
87 rdf:type schema:CreativeWork
88 https://doi.org/10.1046/j.1365-2141.1997.d01-3499.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1050047455
89 rdf:type schema:CreativeWork
90 https://www.grid.ac/institutes/grid.5590.9 schema:Organization
 




Preview window. Press ESC to close (or click here)


...